Business Standard

We continue to increase our reach and access in India, say Sun Pharma execs

Senior Sun Pharma executives speak on a two-pronged strategy for the China market, beginning R&D of biosimilar products, and more

Sun Pharma executives
Premium

(From left) Sun Pharmaceutical Industries CFO C S Muralidharan, and CEO, India business, Kirti Ganorkar

Sohini Das
After posting a 43 per cent rise in Q1 profit after tax (PAT) and 29 per cent jump in sales of specialty products, Sun Pharma is now eyeing to commercialise its specialty products basket in countries outside the US. Speaking to Sohini Das, Sun Pharmaceutical Industries chief financial officer (CFO) C S Muralidharan and chief executive officer (CEO), India business, Kirti Ganorkar, talk about future plans and the incremental innovation in products that they plan to bring to India. Edited excerpts: 

Some of your specialty products like Ilumya and Absorica are now likely to face competition. How are you planning

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jul 31 2022 | 6:13 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com